India to expand authorized import channels for pharmaceuticals and medical devices

India's Health Ministry is moving forward with proposed amendments to the Drugs Rules, 1945, designed to broaden the network of authorized import gateways for pharmaceutical products, medical devices and cosmetics. The regulatory changes represent a significant shift in how such goods enter the Indian market, with officials looking to decentralize import operations beyond existing concentrated hubs.

The expansion of import locations is expected to reduce bottlenecks at current entry points and enhance the efficiency of supply chain operations across the country. By establishing additional authorized gateways, the government aims to facilitate faster clearance of products while maintaining regulatory oversight and quality standards.

The proposed modifications to the drug import framework come as India seeks to strengthen its position as a major pharmaceutical hub. Increased import infrastructure is anticipated to benefit both domestic manufacturers requiring raw materials and international suppliers looking to distribute products within India's vast healthcare market.

The Health Ministry's initiative aligns with broader government efforts to improve healthcare accessibility and streamline regulatory processes. Officials have indicated that the changes will be implemented while preserving stringent quality control measures and compliance requirements that protect consumers and ensure product safety across the pharmaceutical and medical device sectors.